TORL-1-23
Phase 2Small molecule
TORL-1-23 is one of 90 small molecule programs targeting Advanced Cancer. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
89
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
232 competitors in Ovarian Cancer
#DrugCompanyPhaseTrials
1Avastin
RochePhase 3
Hycamtin
MMeitheal
Phase 3
Pegylated Liposomal Doxorubicin
Merck & Co.Phase 3
Femara
NovartisPhase 3
Imfinzi
AstraZenecaPhase 3
Opdivo
Bristol-Myers SquibbPhase 3
Adriamycin
PfizerPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Lynparza
RRisen (Suzhou) Pharma Tech Co., Ltd.
Phase 3
Zepzelca
Jazz PharmaceuticalsPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TORL-1-23. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- TTORL Biotherapeutics, LLC